_____________
Snapshot overview: Programme aimed at supporting preclinical innovative solutions to infectious diseases
_____________
Name: European Investment Bank (EIB)
_____________
Institution/ DG/ Agency responsible at EU-level: N/A
_____________
Work programme: Loans and equity
_____________
Programme: Grants
_____________
Programme budget: Unknown
_____________
Project budget: EUR 7.5 million to EUR 75 million, depending on project
_____________
Type of funding : Bottom up
_____________
Target participants: Innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.
_____________
Programme scope: Infectious diseases
_____________
Participant criteria:
- The promoter should be a large pharmaceutical company, a mid-cap or a small and medium-sized enterprise (SME), a research institute/organisation, a university, a non-profit entity or a special-purpose vehicle (SPV).
- Promoters, sponsors and/or operators must be willing to substantially co-fund the project.
- The beneficiary must be established and operating in one or several of the Member States and Horizon 2020 Associated Countries.
_____________
Project duration: N/A
_____________
Average time from submission to project kick-off: Unknown
_____________
R&D stage: Pre commercial stage investments – Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.
_____________
Intellectual property: The project and/or the intellectual property (IP) development (e.g. clinical trials) can be undertaken outside Member States and Horizon 2020 Associated Countries.
_____________
Project database: Single Electronic Data Interchange Area (SEDIA)
_____________
Status: Open
_____________
Contact details & more information:
